申请人:YASUHARA Akito
公开号:US20100298561A1
公开(公告)日:2010-11-25
A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I]
[wherein R
1
and R
2
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR
3
R
4
or the like (wherein R
3
and R
4
are identical or different, and each represents a hydrogen atom, a C
1-10
alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
一种用于治疗和预防精神障碍,如精神分裂症、焦虑症及其相关疾病、抑郁症、躁郁症和癫痫的药物。该药物拮抗二羧酸谷氨酸代谢型受体II群的作用,在口服给药时显示出高活性。该药物是2-氨基双环[3.1.0]己烷-2,6-二羧酸酯衍生物,由式[I]表示[其中R1和R2相同或不同,每个表示氢原子、C1-10烷基或类似物;X表示氢原子或氟原子;Y表示—OCHR3R4或类似物(其中R3和R4相同或不同,每个表示氢原子、C1-10烷基或类似物;n表示整数1或2)],其药学上可接受的盐或水合物。